Arbor Investment Advisors LLC Makes New $1.03 Million Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Arbor Investment Advisors LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the third quarter, according to its most recent filing with the SEC. The fund purchased 17,950 shares of the biopharmaceutical company’s stock, valued at approximately $1,027,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. GAMMA Investing LLC increased its stake in Halozyme Therapeutics by 96.6% during the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 254 shares during the last quarter. International Assets Investment Management LLC bought a new position in Halozyme Therapeutics in the second quarter worth about $33,000. Whittier Trust Co. acquired a new position in Halozyme Therapeutics in the first quarter valued at approximately $27,000. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Halozyme Therapeutics during the second quarter valued at approximately $49,000. Finally, Toth Financial Advisory Corp acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $57,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. TD Cowen boosted their price objective on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Wells Fargo & Company downgraded shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $58.00 to $62.00 in a research report on Monday, October 7th. Benchmark restated a “buy” rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. The Goldman Sachs Group raised their price target on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $65.00 price objective on shares of Halozyme Therapeutics in a report on Friday. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $60.44.

Halozyme Therapeutics Stock Performance

HALO traded up $1.38 during trading on Monday, hitting $50.63. The stock had a trading volume of 368,392 shares, compared to its average volume of 1,274,695. The firm has a market cap of $6.44 billion, a PE ratio of 20.86, a P/E/G ratio of 0.50 and a beta of 1.27. The company has a current ratio of 7.41, a quick ratio of 6.21 and a debt-to-equity ratio of 5.19. Halozyme Therapeutics, Inc. has a 12 month low of $33.07 and a 12 month high of $65.53. The company has a 50 day simple moving average of $57.99 and a 200-day simple moving average of $51.67.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The business had revenue of $231.40 million for the quarter, compared to the consensus estimate of $204.94 million. During the same quarter last year, the company posted $0.68 earnings per share. Halozyme Therapeutics’s quarterly revenue was up 4.7% on a year-over-year basis. Analysts expect that Halozyme Therapeutics, Inc. will post 3.71 EPS for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total transaction of $592,000.00. Following the sale, the chief executive officer now owns 676,744 shares in the company, valued at approximately $40,063,244.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $59.20, for a total value of $592,000.00. Following the completion of the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at $40,063,244.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Matthew L. Posard sold 9,881 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total transaction of $570,133.70. Following the sale, the director now directly owns 69,874 shares of the company’s stock, valued at approximately $4,031,729.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 89,881 shares of company stock valued at $5,169,834 in the last 90 days. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.